Navigation Links
Misonix Announces the Sale of Its Labcaire Business for up to $5.6 Million
Date:8/4/2009

FARMINGDALE, N.Y., Aug. 5 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today announced the sale of its Labcaire subsidiary to PuriCore International Limited ("PuriCore") for a total purchase price of up to $5.6 million. Misonix received $3,600,000 at closing and a promissory note in the principal amount of $1,000,000, payable in equal installments of $250,000 on the next four anniversaries of the closing. Misonix will also receive a commission paid on sales for the period commencing on the date of closing and ending on December 31, 2013 of 8% of the pass through Automated Endoscope Reprocessing ("AER") and Drying Cabinet products, and 5% of license fees from any chemical licenses marketed by Labcaire directly associated with sales of AER's, specifically for the disinfection of the endoscope. The aggregate commission payable to Misonix is subject to a maximum payment of $1,000,000.

The financial position of Labcaire as of the fiscal year ended June 30, 2009, which is currently unaudited, includes revenues of $14 million and a net loss of $7,000 as compared to revenues of $13.6 million and a net loss of $389,000 for the fiscal year ended June 30, 2008 which was audited as part of the overall Misonix reported results for that period.

Michael A. McManus, Jr., President and Chief Executive Officer stated, "We are very pleased to have completed the transaction with PuriCore. Our strategy has been to create a medical device company that has proprietary, innovative, high margin products that utilize ultrasound as the core technology and we believe the completion of this transaction further supports that goal. Additionally, the cash payment of $3.6 million plus future payments of up to $2 million will give Misonix a solid balance sheet with sufficient cash reserves and no long-term debt. We believe this is extremely important in our current economic environment. We are also confident that Labcaire employees will be part of a combination that will be a stronger organization in the United Kingdom Endoscopic Reprocessing market."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Investor Relations Contact:
    Kevin McGrath
    Cameron Associates, Inc.
    212-245-4577
    Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Receives First Award for Forensic Equipment in China
2. Misonix Announces Participation in 2nd International Workshop on Focal Therapy
3. Misonix Subsidiary, Sonora Medical Systems, Achieves ISO 17025 Accreditation
4. Misonix Announces the Purchase of Patents From ProRhythm, Inc.
5. Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care
6. Misonix Announces Participation in Annual Diabetic Foot Global Conference
7. Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009
8. Misonix Announces New HIFU Distribution Agreement For Portugal
9. Misonix Announces New HIFU Distribution Agreement for Romania and Bulgaria
10. Misonix Announces New Distribution Agreement for Portugal
11. Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... May 22, 2017 , ... ... welcoming new patients with periodontal plastic surgery treatments, including crown lengthening ... Dr. Green provides these esthetic and functional procedures to help patients improve their ...
(Date:5/22/2017)... ... 2017 , ... “Homeostasis: The Journey of a Manic-Depressive” tells the story in ... Rodriguez takes readers on a rollercoaster ride that includes a midnight trek to the ... a dark place where Donald considers suicide. Readers learn how Donald finally achieves ...
(Date:5/22/2017)... ... May 22, 2017 , ... WeightZone Factor a popular ... Factor members to track their exercise patterns, monitor behavioral changes, employ biometric monitoring, ... their mobile phones. It also provides social networks for members with similar interests ...
(Date:5/21/2017)... ... 19, 2017 , ... HealthSmart, the largest independent benefits administrator ... as Chief Information Officer (CIO). He will be joining HealthSmart at the end ... performance. He defines strategic roadmaps by reimagining business processes—bridging the gap between information ...
(Date:5/21/2017)... ... , ... Pot. Reefer. Grass. Mary Jane. No matter what people call it, ... never before. More than a map, new social marketplace Weedable goes beyond ... and for the first time – each other. A social marketplace like no other, ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
(Date:5/6/2017)... May 5, 2017  May is Stroke Awareness Month ... the most important methods to prevent a stroke: monitor ... for Disease Control and Prevention, undetected and uncontrolled hypertension ... Omron, the global leader in personal heart health technology, ... of heart attack and stroke and is advancing a ...
(Date:5/4/2017)... Mass. and SAN DIEGO ... Obstetricians and Gynecologists (ACOG) 2017 Annual Clinical and Scientific ... single-use, self-contained, illuminating medical devices, today announced the launch ... of its OfficeSPEC and ER-SPEC ... the addition of extra-small and extra-large sizes makes OBP ...
Breaking Medicine Technology: